Vaxcyte, Inc.
NASDAQ: PCVX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Grant E. Pickering
- Employees
- 414
- Headquarters
- San Carlos, United States
- IPO year
- 2020
- Market cap
- $7.4B
- Website
- https://vaxcyte.com
Loading PCVX…
Loading profile data…Frequently asked questions about PCVX
What does Vaxcyte, Inc. (PCVX) do?
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phas...
Where does PCVX trade?
Vaxcyte, Inc. (PCVX) trades on the NASDAQ Global Select.
What sector is PCVX in?
Vaxcyte, Inc. (PCVX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Vaxcyte, Inc.?
Grant E. Pickering is the chief executive officer of Vaxcyte, Inc. (PCVX).
Where is Vaxcyte, Inc. headquartered?
Vaxcyte, Inc. is headquartered in United States.
Does PCVX pay a dividend?
Vaxcyte, Inc. (PCVX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PCVX go public?
Vaxcyte, Inc. (PCVX) completed its initial public offering in 2020.